SEC Filing Analysis: ImmunityBio, Inc. (IBRX)

Executive Summary

• Trading Significance: High
• Key Takeaway: Executive Chairman Dr. Patrick Soon-Shiong and his network of entities have reaffirmed a massive 68.9% beneficial ownership stake, underscoring their complete control over the company's strategic direction.
• Market Impact: Neutral, as this is an amendment to a well-known controlling position, but it reinforces the extreme concentration of power.

Company Information

Field	Value
Company	ImmunityBio, Inc.
Ticker Symbol	IBRX
CIK	0001326110
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Patrick Soon-Shiong
CIK	0001189020
Title/Position	Executive Chairman
Relationship	10% Owner, Officer, Director

Transaction Details

This Schedule 13D/A filing is an amendment to a beneficial ownership report, not a record of a new transaction. It updates the public record on the holdings of a major shareholder group.

Field	Value
Form Type	SCHEDULE 13D/A
Date of Event	2025-11-10
Transaction Code	N/A
Security Type	Common Stock, par value $0.0001 per share
Shares Involved	Not applicable
Price Per Share	Not applicable
Total Value	Not applicable
Shares Owned After	743,971,200 (aggregate by reporting group)
Ownership Type	Indirect

Financial Impact Assessment

Holding Materiality

The significance lies in the total stake, not a single transaction.

Metric	Value
Total Holding Value (est.)	~$1,651,616,064
% of Market Cap	~78.6%
Shares Held by Group	743,971,200
% of Shares Outstanding	68.9%
Post-Transaction Ownership	743,971,200 shares (68.9% of outstanding)
Materiality Assessment	Highly Significant

Impact Evaluation

• Market Cap Context: The reporting group's stake, valued at over $1.65 billion, constitutes the vast majority of ImmunityBio's $2.1 billion market capitalization. This is an immense concentration of value in the hands of one insider group.
• Ownership Concentration: At 68.9%, the reporting group, led by Dr. Soon-Shiong, has absolute control over the company. They can dictate the outcome of all shareholder votes, including board elections and major corporate actions. This level of control is rare for a publicly-traded company of this size.
• Dilution Impact: The filing notes the ownership calculation includes 93.1M shares issuable upon conversion of a promissory note and 1.1M shares from stock options. The potential exercise of these instruments is a key component of the group's total control and represents future dilution for other shareholders.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This filing is an amendment that confirms a pre-existing and well-understood control structure. The market has long priced in Dr. Soon-Shiong's controlling stake. Therefore, this update is unlikely to trigger a significant price reaction.

Volume & Sentiment

• Expected Volume Impact: Low. As a routine ownership update, it is not expected to drive trading volume.
• Sentiment Indicator: Neutral. The filing reinforces the status quo rather than providing new bullish or bearish information.

Investment Insights

Positive Market Indicators

• Founder Conviction: The massive, long-term holding demonstrates the founder's deep conviction in the company's future.
• Strategic Stability: A single controlling shareholder ensures strategic stability and a long-term focus, insulating the company from activist pressures.

Risk Factors

• Key-Person Risk: The company's fate is inextricably linked to Dr. Soon-Shiong. Any change in his health, finances, or focus could have an outsized impact.
• Limited Minority Shareholder Influence: Public shareholders have virtually no say in the company's governance or strategic direction.
• Potential for Conflicts of Interest: The complex web of entities controlled by the insider could lead to related-party transactions that may not always align with the interests of minority shareholders.

Key Takeaways

1. Controlled Company: ImmunityBio operates as a controlled company, with Dr. Patrick Soon-Shiong holding decisive power.
2. Status Quo Reaffirmed: This filing confirms the stability of the existing control structure, which is the single most important governance factor for the company.
3. Focus on Execution: For investors, the focus should be less on governance changes and more on the operational and clinical execution directed by the controlling insider.

Additional Context

Transaction Notes

• This is Amendment No. 11 to the original Schedule 13D, indicating a long history of ownership updates. The filing aggregates the holdings of Dr. Soon-Shiong and numerous entities he controls, including Cambridge Equities, LP, NantWorks, LLC, and Nant Capital, LLC.